Evidence map›Paper›PMID 28523463›Full record

ArticleInflammation2017

Immature Exosomes Derived from MicroRNA-146a Overexpressing Dendritic Cells Act as Antigen-Specific Therapy for Myasthenia Gravis.

Weifan Yin, Song Ouyang, Zhaohui Luo, Qiuming Zeng, Bo Hu, Liqun Xu, Yuan Li, Bo Xiao, Huan Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Therapeutically harnessing extracellular vesicles.Nature reviews. Drug discovery · 2022
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weifan YinDepartment of Neurology, the Second Xiangya Hospital, Central South University, Changsha, China.
Song OuyangDepartment of Neurology, The First Hospital in Changsha City, Changsha, China.
Zhaohui LuoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Qiuming ZengDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Bo HuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Liqun XuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Yuan LiDepartment of Neurology, The First Hospital in Changsha City, Changsha, China.
Bo XiaoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Huan YangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China. 258022567@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myasthenia gravis (MG) is a neurological autoimmune disease characterized by fluctuating weakness of certain voluntary muscles. Current treatments for MG are largely directed at suppressing the whole immune system by using immunosuppressants or glucocorticoids and often cause several side effects. The ideal therapeutic methods for MG should suppress aberrant immunoactivation specifically, while retaining normal function of the immune system. In this study, we first produced exosomes from microRNA-146a overexpressing dendritic cells (DCs). Then, we observed suppressive effects of those exosomes in experimental autoimmune myasthenia gravis (EAMG) mice. Results showed that exosomes from microRNA-146a overexpressing DCs expressed decreased levels of CD80 and CD86. In experimental autoimmune MG, exosomes from microRNA-146a overexpressing DCs suppressed ongoing clinical MG in mice and altered T helper cell profiles from Th1/Th17 to Th2/Treg both in serum and spleen, and the therapeutic effects of those exosomes were antigen-specific and partly dose dependent. All the findings provide experimental basis for antigen-specific therapy of MG.

Indexed as

MicroRNAsAnimalsB7-1 AntigenB7-2 AntigenDendritic CellsExosomesHeterograftsMiceMyasthenia Gravis, Autoimmune, ExperimentalT-Lymphocytes, Helper-InducerT-Lymphocytes, RegulatoryB7-1 AntigenB7-2 AntigenMicroRNAsMirn146 microRNA, mousedendritic cellexosomesmicroRNAmyasthenia gravistherapy

Identifiers

PMID28523463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.